메뉴 건너뛰기




Volumn 169, Issue 4, 2013, Pages 934-938

Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; LACTATE DEHYDROGENASE; NITROGEN; STEROID; UREA; VEMURAFENIB;

EID: 84885650463     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12555     Document Type: Article
Times cited : (31)

References (12)
  • 1
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman PB, Hauschild A, Robert C, et al,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
    • (2011) N Engl J Med , vol.364 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 2
    • 84863116743 scopus 로고    scopus 로고
    • Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
    • Sosman JA, Kim KB, Schuchter L, et al,. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14.
    • (2012) N Engl J Med , vol.366 , pp. 707-714
    • Sosman, J.A.1    Kim, K.B.2    Schuchter, L.3
  • 3
    • 10244236377 scopus 로고    scopus 로고
    • Acute renal failure - Definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group
    • Bellomo R, Ronco C, Kellum JA, et al,. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-12.
    • (2004) Crit Care , vol.8
    • Bellomo, R.1    Ronco, C.2    Kellum, J.A.3
  • 4
    • 77955895112 scopus 로고    scopus 로고
    • Acute interstitial nephritis
    • Praga M, González E,. Acute interstitial nephritis. Kidney Int 2010; 77: 956-61.
    • (2010) Kidney Int , vol.77 , pp. 956-961
    • Praga, M.1    González, E.2
  • 5
    • 77956513286 scopus 로고    scopus 로고
    • Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
    • Bollag G, Hirth P, Tsal J, et al,. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467: 596-9.
    • (2010) Nature , vol.467 , pp. 596-599
    • Bollag, G.1    Hirth, P.2    Tsal, J.3
  • 6
    • 77954376912 scopus 로고    scopus 로고
    • RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models
    • Yang H, Higgins B, Kolinsky K, et al,. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010; 70: 5518-27.
    • (2010) Cancer Res , vol.70 , pp. 5518-5527
    • Yang, H.1    Higgins, B.2    Kolinsky, K.3
  • 7
    • 70350683587 scopus 로고    scopus 로고
    • Acute kidney injury in patients with inactive cytochrome P450 polymorphisms
    • Leung N, Eirin A, Irazabal MV, et al,. Acute kidney injury in patients with inactive cytochrome P450 polymorphisms. Ren Fail 2009; 31: 749-52.
    • (2009) Ren Fail , vol.31 , pp. 749-752
    • Leung, N.1    Eirin, A.2    Irazabal, M.V.3
  • 8
    • 0030338073 scopus 로고    scopus 로고
    • Anti-cytochrome P450 autoantibodies in drug-induced disease
    • Beaune P,. Anti-cytochrome P450 autoantibodies in drug-induced disease. Eur J Haematol Suppl 1996; 60: 89-92.
    • (1996) Eur J Haematol Suppl , vol.60 , pp. 89-92
    • Beaune, P.1
  • 9
    • 84868120907 scopus 로고    scopus 로고
    • Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial
    • Long GV, Trefzer U, Davies MA, et al,. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 1087-95.
    • (2012) Lancet Oncol , vol.13 , pp. 1087-1095
    • Long, G.V.1    Trefzer, U.2    Davies, M.A.3
  • 10
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
    • Hauschild A, Grob J-J, Demidov LV, et al,. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-65.
    • (2012) Lancet , vol.380 , pp. 358-365
    • Hauschild, A.1    Grob, J.-J.2    Demidov, L.V.3
  • 11
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal-cell carcinoma
    • Escudier B, Eisen T, Stadler WM, et al,. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34.
    • (2007) N Engl J Med , vol.356 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 12
    • 77949326926 scopus 로고    scopus 로고
    • Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib
    • Overkleeft ENM, Goldschmeding R, van Reekum F, et al,. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. Ann Oncol 2010; 21: 184-5.
    • (2010) Ann Oncol , vol.21 , pp. 184-185
    • Overkleeft, E.N.M.1    Goldschmeding, R.2    Van Reekum, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.